Goldman Sachs on Agios Pharma (AGIO): 'we see a favorable risk-benefit profile'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $39.00 price target on Agios Pharma (NASDAQ: AGIO).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
